A major shift is underway in how traumatic brain injuries are diagnosed, documented, and litigated. In February 2026, pharmaceutical giant Roche launched a landmark Phase II/III clinical trial — registered as NCT07455136 — to advance blood-based diagnostic testing for traumatic brain injury using two critical protein biomarkers: GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin carboxy-terminal hydrolase L1). With a projected completion date of March 2028, this trial is accelerating what many brain injury attorneys already know: blood biomarkers TBI diagnosis settlement evidence is no longer a future concept — it is the present standard reshaping personal injury claims across the country in 2026.
Roche’s Phase II/III Trial and the Science Behind GFAP and UCH-L1
Roche’s clinical trial NCT07455136, which began on February 9, 2026, and received a status update in June 2026, represents one of the most significant investments in objective TBI diagnostics since the FDA cleared Abbott’s i-STAT TBI Plasma test in 2021. The i-STAT test, which measures both GFAP and UCH-L1 levels directly from a blood draw, has also been registered in Europe, signaling global adoption. Roche’s Phase II/III trial builds on this foundation, aiming to further validate, standardize, and expand clinical use of these biomarkers across diverse patient populations and injury severities.
GFAP is a structural protein found in astrocytes — the star-shaped glial cells of the brain. When the brain sustains trauma, astrocytes release GFAP into the bloodstream. Critically, GFAP is largely unaffected by extracranial (non-brain) trauma, which means elevated GFAP levels in blood are a targeted signal of brain-specific injury — not a byproduct of general bodily harm. This distinction is enormously important in litigation, where defense attorneys often argue that physical injuries outside the skull could explain a plaintiff’s symptoms.
UCH-L1 is a neuron-specific enzyme involved in protein degradation. Because it is expressed almost exclusively in neurons, elevated UCH-L1 in the bloodstream following a traumatic event provides direct, measurable evidence of neuronal damage. Together, GFAP and UCH-L1 give clinicians — and now, courts — two independent, scientifically validated markers of brain cell injury. For anyone pursuing a brain injury claim in 2026, blood biomarkers TBI diagnosis settlement evidence built on GFAP and UCH-L1 results may become the cornerstone of a compelling damages case. To understand how this evidence may factor into your overall claim value, explore our personal injury settlement calculator.
Blood Tests vs. CT Scans: What the Research Shows in 2026
For decades, CT imaging has been the front-line diagnostic tool for emergency TBI assessment. Yet CT scans carry well-documented limitations: they expose patients to ionizing radiation, they are costly, and — most critically for mild TBI cases — they frequently return normal results even when a genuine brain injury is present. This is the diagnostic gap that has allowed insurance carriers to dismiss thousands of legitimate TBI claims as “subjective” or “unverifiable.”
A 2024 systematic review published on PubMed (NCBI) confirmed that blood-based biomarker testing can significantly reduce unnecessary CT scans in mild TBI management — protecting patients from radiation while simultaneously generating objective, laboratory-documented evidence of injury. This is not a replacement for imaging; it is a complementary tool that fills the diagnostic void where CT fails.
The landmark TRACK-TBI study, one of the most comprehensive TBI research programs in history, demonstrated that GFAP shows good-to-excellent diagnostic performance across all age groups in discriminating between TBI diagnostic categories — and critically, this performance holds for up to three or more days post-injury. This time window is particularly relevant in personal injury litigation: plaintiffs who did not seek immediate emergency care still have a window during which their blood biomarker results can document the injury. The table below summarizes the key distinctions between these diagnostic approaches.
| Diagnostic Method | Detects Mild TBI | Brain-Specific | Radiation Exposure | Litigation Value | Post-Injury Detection Window |
|---|---|---|---|---|---|
| CT Scan | Often negative in mild TBI | Structural only | Yes | Limited (normal result used against plaintiff) | Hours |
| MRI | Better than CT, still limited | Structural/functional | No | Moderate to strong | Days to weeks |
| GFAP Blood Biomarker | Yes | Yes (glial-specific) | No | Strong — objective protein evidence | Up to 3+ days (TRACK-TBI) |
| UCH-L1 Blood Biomarker | Yes | Yes (neuron-specific) | No | Strong — neuron damage documentation | Up to 48 hours, combined use extends window |
| Subjective Symptom Reporting | Yes (patient-reported) | No | No | Weak alone — easily challenged by defense | Ongoing |
Sources: TRACK-TBI Study; 2024 PubMed systematic review on blood biomarkers in mild TBI management; FDA i-STAT TBI Plasma test clearance documentation (2021); Roche NCT07455136 trial registry (2026).
How Blood Biomarker Evidence Strengthens TBI Settlement Cases
The single greatest challenge in mild TBI litigation has always been the “invisible injury” problem. A plaintiff reports cognitive fog, chronic headaches, memory disruption, and emotional dysregulation — but a CT scan returns normal, and an insurance adjuster labels the claim as exaggerated or psychosomatic. This is where blood biomarkers TBI diagnosis settlement evidence fundamentally changes the legal landscape in 2026.
When a treating physician orders a GFAP/UCH-L1 blood panel — now a standard-of-care option at many emergency departments — and the results return elevated, that laboratory report becomes a dated, physician-ordered, laboratory-documented piece of objective evidence. It is timestamped, generated by a certified medical laboratory, and grounded in peer-reviewed science that insurance carriers themselves are increasingly aware of. Defense teams can no longer credibly argue that “there’s no proof of brain injury” when a blood test result, generated within days of the incident, shows quantifiable levels of brain-specific proteins in the plaintiff’s bloodstream.
For TBI cases arising from motor vehicle collisions — one of the leading causes of traumatic brain injury — this evidence is particularly powerful. If you were injured in a crash, understanding how biomarker documentation may influence your compensation begins with evaluating your claim through our car accident settlement calculator. The combination of a positive biomarker result, documented symptoms, and expert medical testimony creates a three-layer evidentiary structure that is considerably harder for defense counsel to dismantle than symptom reporting alone.
Key ways biomarker evidence strengthens TBI settlement negotiations include:
- Corroborating subjective complaints with objective laboratory data, eliminating the “malingering” narrative
- Establishing injury severity through quantified protein levels rather than patient self-report scales
- Documenting a causal timeline — the blood test is ordered by a physician within days of the incident, creating an indisputable medical record linking the event to the injury
- Countering normal CT/MRI results that defense attorneys have historically used to minimize claim value
- Supporting future damages arguments by demonstrating that measurable neurological damage occurred, even when imaging was negative
Insurance Defense Tactics and Why Biomarkers Close the Door
Insurance defense strategies in TBI claims have long relied on a predictable playbook: challenge the mechanism of injury, question the severity, emphasize normal imaging results, and characterize symptoms as pre-existing or exaggerated. In 2026, the emergence of validated blood biomarkers TBI diagnosis settlement evidence neutralizes the most powerful of these tactics.
Insurance carriers are not unaware of this shift. Industry literature and claims management guidance have increasingly referenced biomarker validation in peer-reviewed research. Carriers know that a plaintiff presenting elevated GFAP and UCH-L1 results — backed by the growing body of clinical evidence, including Roche’s ongoing NCT07455136 trial — presents a fundamentally stronger case than one relying on symptom diaries alone. This awareness is already influencing how insurers approach early settlement negotiations in 2026, particularly in states where courts have shown receptivity to biomarker evidence.
For claims involving large commercial vehicle collisions — where TBI severity and long-term damages can be particularly significant — biomarker documentation may be even more decisive. Victims of truck accidents can explore how objective injury evidence factors into compensation with our truck accident calculator. The Centers for Disease Control and Prevention (CDC) continues to recognize TBI as a serious public health issue affecting millions of Americans annually, and the evolution toward biomarker-confirmed diagnosis aligns with broader public health goals of accurate injury identification and appropriate care allocation.
Defense teams face a new challenge in 2026: when a plaintiff has a dated laboratory report showing elevated GFAP or UCH-L1, arguing that no brain injury occurred requires contradicting not only the plaintiff’s physician but also the FDA-cleared diagnostic technology and an expanding body of Phase II/III clinical trial data. That is a much more difficult position to sustain before a jury or in mediation.
What Brain Injury Victims and Their Attorneys Should Do in 2026
The rapid standardization of blood biomarker testing in emergency and urgent care settings means that TBI victims and their legal representatives must be proactive about preserving this evidence. Here is what matters most in 2026:
- Seek immediate medical evaluation after any head trauma — specifically request or ensure your treating physician considers GFAP/UCH-L1 biomarker testing as part of the workup, particularly if CT results are normal and symptoms persist.
- Preserve all laboratory records including the specific numerical values of GFAP and UCH-L1 results, the ordering physician’s notes, and the date the test was administered relative to the date of injury.
- Document the symptom timeline alongside biomarker results — the combination of objective protein data and a contemporaneous symptom diary creates a compelling evidentiary record.
- Retain a medical expert who can explain biomarker significance to a jury or arbitrator in clear, accessible terms, connecting the laboratory result to the plaintiff’s functional impairments.
- Understand how biomarker evidence intersects with damages calculations — elevated biomarker results may support claims for future medical care, lost earning capacity, and non-economic damages. Understanding how these factors contribute to your overall claim value is an important early step.
In rare and tragic cases where TBI results in fatal outcomes, biomarker evidence documented prior to death can also support the surviving family’s legal claim. Families navigating such circumstances may find it useful to explore general damages frameworks through a wrongful death calculator as a starting point for understanding their options. For broader legal context on how personal injury evidence standards apply across jurisdictions, Cornell Law School’s Legal Information Institute provides authoritative reference material on evidentiary rules.
Frequently Asked Questions About Blood Biomarkers and TBI Settlement Evidence
What are GFAP and UCH-L1, and why do they matter for my TBI claim?
GFAP (glial fibrillary acidic protein) is a brain-specific protein released by damaged astrocytes after head trauma, and UCH-L1 (ubiquitin carboxy-terminal hydrolase L1) is a neuron-specific enzyme released when neurons are damaged. Both are measurable through a blood draw. Because GFAP is unaffected by injuries outside the brain, elevated levels are a targeted indicator of brain-specific trauma. In 2026, these biomarkers are FDA-cleared diagnostic tools, and documented elevated results constitute objective, laboratory-verified evidence of brain injury — making them highly valuable as blood biomarkers TBI diagnosis settlement evidence in personal injury claims where CT scans returned normal or where defense teams are challenging injury validity.
Can a blood biomarker test detect a mild TBI that a CT scan missed?
Yes. This is one of the most significant clinical and legal advantages of GFAP and UCH-L1 testing in 2026. CT scans are primarily designed to detect structural abnormalities such as bleeds or fractures, and they frequently return normal results in mild TBI cases even when genuine neurological injury has occurred. A 2024 systematic review published on PubMed found that blood biomarker panels can reduce unnecessary CT scanning in mild TBI management while providing objective evidence of injury. The TRACK-TBI study further confirmed that GFAP demonstrates good-to-excellent performance in discriminating TBI diagnostic groups across all age groups for up to three or more days post-injury, giving plaintiffs a meaningful window to document their injury through blood testing even if they did not undergo imaging immediately.
Will insurance companies accept blood biomarker results as evidence of TBI?
In 2026, insurance carriers are increasingly aware of the peer-reviewed validation behind GFAP and UCH-L1 biomarkers, including the FDA’s clearance of the i-STAT TBI Plasma test in 2021 and its European registration, as well as Roche’s ongoing Phase II/III clinical trial NCT07455136. While individual carriers’ claims handling practices vary, the scientific legitimacy of these biomarkers is difficult to dispute when results are documented in a certified medical laboratory report ordered by a treating physician. Defense teams that previously dismissed “invisible” TBI injuries now face a much more credible body of objective evidence. Plaintiffs with documented biomarker results are generally in a substantially stronger negotiating position than those relying on symptom reporting alone.
How soon after a head injury should I get a GFAP/UCH-L1 blood test?
Based on current research, including findings from the TRACK-TBI study, GFAP levels can be reliably detected in blood for up to three or more days following a traumatic brain injury. UCH-L1 is generally most detectable within approximately 48 hours post-injury, though combined use of both biomarkers can extend the useful diagnostic window. The practical recommendation for TBI victims in 2026 is to seek medical evaluation as promptly as possible after any head trauma — ideally within the first 24 to 48 hours — and specifically to ask whether GFAP/UCH-L1 testing is available and appropriate for your clinical presentation. The sooner these results are documented, the stronger the evidentiary link to the specific incident causing your injury.
What is Roche’s NCT07455136 trial, and how does it affect TBI litigation going forward?
Roche’s Phase II/III clinical trial, registered as NCT07455136 and launched on February 9, 2026, with a status update in June 2026, is designed to further validate and standardize blood-based TBI diagnostics using GFAP and UCH-L1 biomarkers, with a projected completion date of March 2028. For TBI litigation, this trial matters for two reasons. First, as Phase II/III trial data accumulates, the scientific foundation for these biomarkers becomes even more robust — making it harder for defense experts to challenge their reliability in court. Second, the involvement of a major global pharmaceutical company signals that blood biomarker testing for TBI is transitioning from an emerging tool to a widely accepted clinical standard, which strengthens the foundation for using blood biomarkers TBI diagnosis settlement evidence in personal injury claims for years to come.
Legal Disclaimer: The information provided on this website is for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Related reading: Forceps Birth Injury Verdict & Damages: How A $108.6M Award Reflects The Lifetime Cost Of Negligent Delivery
Related reading: Full Self-Driving Crashes & Legal Liability: 2026 Settlement & Fault Shift
Robert Callahan is a TBI and Catastrophic Injury Researcher with extensive knowledge of personal injury law and settlement values across the United States. With years of experience analyzing brain injury / tbi claims only cases, Robert helps injury victims understand their legal rights and the potential value of their claims. Robert is not an attorney and the information provided is for educational purposes only.